Talphera (NASDAQ:TLPH) Upgraded at Wall Street Zen

Key Points

• Wall Street Zen upgraded Talphera to “Hold,” while analysts’ overall consensus remains “Hold” with an average price target of $3.00. Ratings include two Buys, one Hold and one Sell.
• Talphera opened at $1.43, with a $74.22 million market capitalization and a share price near its one-year high of $1.57. The company reported a quarterly loss of $0.04 per share, beating estimates for a $0.07 loss.
• Institutional ownership stands at 37.67%, with several funds increasing their positions, including Nantahala Capital Management and Renaissance Technologies. Talphera is developing specialty pharmaceutical products including Niyad, LTX-608, Fedsyra and PFS-02.

Talphera (NASDAQ:TLPH - Get Free Report) was upgraded by research analysts at Wall Street Zen to a "hold" rating in a research note issued on Saturday.

Several other analysts have also recently issued reports on the company. Westpark Capital assumed coverage on Talphera in a research note on Thursday, April 30th. They issued a "buy" rating and a $3.00 price objective on the stock. HC Wainwright assumed coverage on Talphera in a research report on Friday, June 5th. They issued a "buy" rating and a $3.00 price target on the stock. Weiss Ratings reiterated a "sell (d-)" rating on shares of Talphera in a research note on Friday, July 17th. Finally, Zacks Research raised Talphera to a "hold" rating in a research report on Monday, June 8th. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of "Hold" and an average target price of $3.00.

Talphera Stock Performance

NASDAQ TLPH opened at $1.43 on Friday. The firm has a market cap of $74.22 million, a price-to-earnings ratio of -4.61 and a beta of 0.69. The firm has a 50 day simple moving average of $1.14 and a 200-day simple moving average of $0.95. Talphera has a one year low of $0.39 and a one year high of $1.57.

Talphera (NASDAQ:TLPH - Get Free Report) last released its earnings results on Wednesday, May 13th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.07) by $0.03. Equities analysts predict that Talphera will post -0.26 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the business. Nantahala Capital Management LLC boosted its holdings in Talphera by 75.3% in the third quarter. Nantahala Capital Management LLC now owns 3,492,519 shares of the company's stock valued at $3,120,000 after purchasing an additional 1,500,000 shares in the last quarter. Empery Asset Management LP purchased a new position in Talphera in the fourth quarter valued at approximately $1,520,000. Cantor Fitzgerald L. P. acquired a new stake in Talphera during the fourth quarter worth approximately $658,000. Renaissance Technologies LLC raised its holdings in Talphera by 412.6% during the fourth quarter. Renaissance Technologies LLC now owns 257,380 shares of the company's stock worth $293,000 after purchasing an additional 207,166 shares in the last quarter. Finally, AIGH Capital Management LLC lifted its position in shares of Talphera by 4.6% during the 4th quarter. AIGH Capital Management LLC now owns 4,661,502 shares of the company's stock worth $5,314,000 after buying an additional 206,957 shares during the last quarter. 37.67% of the stock is owned by institutional investors and hedge funds.

About Talphera

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source